Comment
Author: Admin | 2025-04-28
The serum concentration of Olaparib. Avoid combinationOpioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Consider therapy modificationOrlistat: May decrease the serum concentration of Anticonvulsants. Monitor therapyOrphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. Avoid combinationOsimertinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Osimertinib. Consider therapy modificationOXcarbazepine: CYP3A4 Inducers (Strong) may decrease the serum concentration of OXcarbazepine. Specifically, the concentrations of the 10-monohydroxy active metabolite of oxcarbazepine may be decreased. Monitor therapyOxomemazine: May enhance the CNS depressant effect of CNS Depressants. Avoid combinationOxyCODONE: PHENobarbital may enhance the CNS depressant effect of OxyCODONE. PHENobarbital may decrease the serum concentration of OxyCODONE. Management: Avoid use of oxycodone and phenobarbital when possible. Monitor for respiratory depression/sedation. Because phenobarbital is also a strong CYP3A4 inducer, monitor for decreased oxycodone efficacy and withdrawal if combined. Consider therapy modificationPalbociclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Palbociclib. Avoid combinationPanobinostat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Panobinostat. Avoid combinationParaldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. Avoid combinationPAZOPanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of PAZOPanib. Avoid combinationPerampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel. Management: Increase the perampanel starting dose to 4 mg/day when perampanel is used concurrently with moderate and strong CYP3A4 inducers. Consider therapy modificationPerampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they
Add Comment